Peter Alping

PhD Student

Peter Alping

Hi!

My name is Peter and I'm a PhD student at the Department of Clinical Neuroscience, Karolinska Institutet, Sweden. My research is focused on pharmacoepidemiological studies of disease modifying therapies for multiple sclerosis.

Publications

  1. P. Alping, T. Frisell, L. Novakova, P. Islam-Jakobsson, J. Salzer, A. Bjorck, M. Axelsson, C. Malmestrom, K. Fink, J. Lycke, A. Svenningsson and F. Piehl, “Rituximab versus fingolimod after natalizumab in multiple sclerosis patients,” Ann Neurol, vol. 79, no. 6, pp. 950-8, 2016.
    [BibTeX]

    @article{Alping2016,
    	author = {Alping, P. and Frisell, T. and Novakova, L. and Islam-Jakobsson, P. and Salzer, J. and Bjorck, A. and Axelsson, M. and Malmestrom, C. and Fink, K. and Lycke, J. and Svenningsson, A. and Piehl, F.},
    	title = {Rituximab versus fingolimod after natalizumab in multiple sclerosis patients},
    	journal = {Ann Neurol},
    	year = {2016},
    	volume = {79},
    	number = {6},
    	pages = {950--8},
    	doi = {http://doi.org/10.1002/ana.24651}
    	}
    				
  2. J. Salzer, R. Svenningsson, P. Alping, L. Novakova, A. Bjorck, K. Fink, P. Islam-Jakobsson, C. Malmestrom, M. Axelsson, M. Vagberg, P. Sundstrom, J. Lycke, F. Piehl and A. Svenningsson, “Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy,” Neurology, 2016.
    [BibTeX]

    @article{Salzer2016,
    	author = {Salzer, J. and Svenningsson, R. and Alping, P. and Novakova, L. and Bjorck, A. and Fink, K. and Islam-Jakobsson, P. and Malmestrom, C. and Axelsson, M. and Vagberg, M. and Sundstrom, P. and Lycke, J. and Piehl, F. and Svenningsson, A.},
    	title = {Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy},
    	journal = {Neurology},
    	year = {2016},
    	doi = {http://doi.org/10.1212/wnl.0000000000003331}
    				}
    				

Peter Alping, PhD Student

Department of Clinical Neuroscience

Karolinska Institutet, Stockholm

E-mail: peter.alping@ki.se